Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance
1/ 💡While much of the immunology field is fixated on immune reset in B cells and autoimmunity, a quieter version of the same idea is emerging in cardio-immunology. 🫀 Except we are not talking about lymphocytes. This is all about tissue-resident macrophages. And the outcome is not immune tolerance. It is cardioprotection.
PBMs and GPOs Inflate Drug Prices, Hide Billions
“Bullshit” — The New Way Health Giants Hide Billions" https://t.co/6PcmoY1pmh This PBM GPO investigative story makes my blood boil... these intermediaries are why the list-to-net spread for many drugs is over 50% in the US... siphoning off dollars at the expense of...
Massive Single‑cell Data: Deeper Insight or Just Bigger Counts?
1/ Another single-cell study drops. 500,000 cells sequenced. More UMAP plots. More clusters. But here’s the question: Are we learning more—or just counting better? 🧵 https://t.co/nuYRT0GTAq
Claude Code Boosts Bioinformatics Efficiency Tenfold
learn how to use Claude Code. It's changing how I am working as a bioinformatician. If you know what you want, it 10x my efficiency. It is scary to see its power. but like any technology, it will cause disruption. We just need to...
Sequencing Depth Drives Artifacts, Confounds scRNA‑seq Analyses
1/ Per-cell sequencing depth is a major technical effect in scRNA-seq. Different depths change what the data looks like and create artifacts that propagate into clustering, DE, and downstream modeling. And depth heterogeneity itself becomes the signal your methods pick up. https://t.co/RlAD1ONGVX
Transparent Valuation Links Investor Thesis to Share Price
Transparency in valuation is a good thing. People may have different assumptions but it’s important to understand how your thesis as an investor translates into a share price. Thank your for posting @Biotech2k1
Context and Competition: Key Framework for Biotech Investors
The context of the data matter. How does it stack up against the competition? Is there other competition? This framework will help investors organise their thoughts #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/jKBHRAXsch
Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge
That blowing sound you hear is from hundreds of biotech ceos blowing the dust off their S-1s, fingers crossed.
Political Appointees Cut Universal Meningococcal Vaccine Recommendation
When political appointees rewrote U.S. vaccination policy, they removed meningococcal vaccine from the list of those recommended for all kids. It protects against a rare but devastating illness with a high fatality rate. @jakescottMD's take is worth the read. https://t.co/poDJrAZQtO
CEO Meeting Canceled; Conference Presentation Likely Scrapped
$RVMD - I had a meeting scheduled with the CEO on Monday morning. The company just cancelled. #JPM26 RevMed is also scheduled to present at the conference on Monday morning. I assume that’s cancelled, too, but I don’t have confirmation.
Biotech TV Takes Over Union Square with Industry Leaders
Biotech TV is going to blanket Union Square this year. Starting Sunday, we'll have @ByAmyBrown @RS_Flinn @chloeckirk and myself hustling around town with the industry's top leaders. Please tune in. https://t.co/mtJTzUF5Sd
NTLA’s 8‑K Reveals Liver Failure Death From Sepsis
Context: $NTLA just 8K'd (not a PR, hmmm wonder why) that their Hy's Law patient's autopsy showed ruptured GI ulcer and sepsis as the ultimate cause of death. Anyone saying this is not related to the liver failure is showing...
Predicting $20B+ Biotech M&A Deal by 2026
One of my #JPM26 predictions for 2026 is that we'll see a $20B-plus M&A deal in biotech. So here's hoping any RevMed deal comes after Monday morning. https://t.co/5pe4ymAILt
Sepsis Often Leads to Death In
Hey @grok is sepsis a common proximate cause of death in patients with drug induced liver failure?
Flu Deaths Rise as Child Vaccination Rates Fall
1. There's a new FluView report from #CDC. Let's dive in. CDC was informed of 7 more kids who've died from #flu, bringing the season's toll to 17. Sadly, this number is going to rise. Vaccine uptake among kids has been...
Biotech Deal Surge: Wnt, NLRP3, GLP‑1, and More
Your Weekly Biotech News Fix | Ep. 901 Designed to be consumed as a quick scroll 🧬 Parabilis - $305M Wnt bet 🔥 $LLY - Buys $VTYX (NLRP3) 🎯 $PFE - Cartography antigen deal 🧲 $AMGN - Dark Blue acquisition 🦠 $GSK / $IONS - HBV...
CHIP Clones Raise Cardiovascular Risk in Cancer Survivors
More evidence that blood stem cell clones (CHIP), common with increasing age, increase the risk of cardiovascular events, from people treated with cancer https://t.co/56YDjxshjg https://t.co/kdUksoCFmI
Red Blood Cells Drive Vascular Damage in Long‑Term Type 2 Diabetes
Implicating red cells as an underpinning of the vascular damage seen with long duration Type 2 diabetes https://t.co/FzvmreCtn7 https://t.co/MdgpHmpRvo
Nominate Under‑35 Biotech Trailblazers for 2026 Award
Do you know an up and coming someone killing it in biotech? If they're under 35 years of age, please nominate them for the 2026 Technology Review 35 Innovators Under 35 Award. (or just email me. address is in bio) https://t.co/90fwj4GjNU
Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns
It's good to see new trial readouts at #GI26, although there are 7 reasons to be bearish about the zanidatamab data in gastric cancer: https://t.co/g2MbrPI7Iu https://t.co/tBY2yJ6YMe
APOE Ε3/Ε4 Alleles Drive Majority of Alzheimer’s Cases
A new report claims that the APOE gene alleles accounts for the vast majority of Alzheimer's cases: "Without strong underlying risks from APOE ε3 and ε4, almost all AD and half of all dementia would not occur." https://t.co/KgRFx36WOn
Linking DNA Mutations to Gene Expression in Single Cells
Genotype-to-phenotype mapping of somatic clonal mosaicism via single-cell co-capture of DNA mutations and mRNA transcripts https://t.co/6Lss1ukbvp https://t.co/bGwnmQEYfI
UCB Should Demand Label Change; Sonelokimab Inferior
“THAT WILL DECIMATE THE COMPETITION” If the FDA is dumb enough to put a 29% delta on the $MLTX label, UCB should simply request a label change to include *their* P2 efficacy data on the label….where their delta was ***36%***. 36>29 for...
US Cuts Childhood Vaccines, Lagging Behind Peers
Did slashing multiple vaccines from the childhood vaccine schedule bring the US in line with other countries? In a word, no. The US now recommends all kids be protected against fewer diseases than South Korea, Israel, Saudi Arabia, Taiwan &...
AI Accelerates Answers, but Domain Knowledge Solves Problems
1/ AI tools are useless if you don't know what you're looking for. I use Perplexity for search. But the AI didn't solve my IGV bug - my domain knowledge did. The AI just helped me find the answer faster. https://t.co/zi2e2FbO5O
ASND Combo Shows Robust Growth, Heads to Phase 3
$ASND -2.5% Looks approvable (priority review; class precedent). Combo = upside optionality, not the label. COACH Wk-52 open-label Ph2 (n=21) CNP + hGH >AGV: 8.8 (naïve) / 8.42 cm/yr (prior-CNP), >97th pct vs avg-stature >Z-score: +1.02 / +0.86; proportionality/arm-span up; bone age “consistent” >AEs...
UniQure Secures FDA Type A Meeting
$QURE +13% uniQure Announces Type A Meeting Scheduled with FDA 🍿 uniQure Announces Type A Meeting Scheduled with FDA https://t.co/iqZkaNYD7Z https://t.co/lRcR6vgV0D
U.S. Becomes Outlier in Global Vaccine Schedules
Fact check: When it comes to vaccine schedules, the U.S. is now the outlier STAT analysis shows top officials have put the country out of step with peer nations By @HelenBranswell https://t.co/t8ZmqatU1U
Flu Vaccine Shields Heart: Prevents Heart Attacks
Remember: Influenza causes myocardial infarction, heart attacks. One of the best ways to protect your heart health is to keep up with your flu vaccine. Link to @nejm article here and attached. https://t.co/yeHUdEClyf
Baby KJ Scientist Launches Aurora Therapeutics for Personalized CRISPR
Key scientist from Baby KJ team launches startup to scale personalized CRISPR medicines Aurora Therapeutics is one of several efforts vying for space in the growing field Great writing from @Jasonmmast and @ADeAngelis_bio https://t.co/kbDJxY6Sq5
INSM Beats Q4 Forecast, 2025 Revenue Exceeds Expectations
$INSM pre-announces Q4 Brinspuri sales of $144.6M. Consensus $67M, per Visible Alpha. Total '25 revenue $606.4 vs consensus $523M 2026 Arikayce revenue forecast $450-470M vs consensus $488M https://t.co/LhY6SRoTY3
Market Unconvinced: KYRS Needs Functional Data
$KYRS +1% Nice science, market not convinced. KB407 shows delivery + CFTR protein in bronchoscopic biopsies, but no sweat chloride/NPD/FEV1. End of day, PD != clinical translation. Also a crowded CF GTx race = priced in. $FDMT 4D-710 (ppFEV1/LCI signals),...
Baby KJ Scientist Launches Startup to Scale Personalized CRISPR Therapies
Key scientist from Baby KJ team launches startup to scale personalized CRISPR medicines https://t.co/7RY4SKrx9Y via @Jasonmmast @ADeAngelis_bio
Know the FDA Process: Key to Biotech Investment Success
Investors should understand the #FDA regulatory process well. Here is a quick summary At each step investors should ask themselves if the company is developing things in a way that will satisfy the FDA Until a drug is approved the FDA is...
Independent Low-Cost Vaccines Keep Pfizer Out of Markets
ANS: I don’t take a dime from Pfizer or any other big pharma company. If and when you decide to visit a library instead of relying on conspiracy sites, you’ll find we develop low cost, patent free vaccines that bypass...
JPM Acts as Audit, Reveals Biotech Translation Friction
JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
Investors Now Require Clean Data and Clear Milestones
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx
Merck in Talks to Acquire Revolution Medicines, Deal Uncertain
Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology...
Multi-Omic Atlas Shows Women’s Stronger Immunity, Age‑Related Decline
We're learning more about our immune system from a new, comprehensive, multi-omic atlas in @ScienceMagazine today, such as the stronger immune system in women and the age-related features of immunosenescence https://t.co/4B85BwohBb https://t.co/DHNIUKcQmE
AlphaFold Sparks Surge in Genome-Wide Drug Discovery
In the post-AlphaFold era, drug discovery is on a tear —Genome-wide virtual screening @ScienceMagazine https://t.co/GPyjSK6PcM —Transforming the industry in many ways @TheEconomist https://t.co/ppAMkbFqMp
Lilly Tests Zepbound to Drive Taltz Sales
$LLY runs a psoriatic arthritis marketing study of Zepbound hoping to boost sales of Taltz. @elaineywchen sees right through it. Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms https://t.co/pcmEhIZgWY
Rampart's Fall Highlights Struggles in Legacy Gene Therapy
Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...
AI-Driven Tracking of Tumor Evolution Reshapes Cancer Therapy
The plan to revolutionize cancer treatment by tracking and responding to evolution of tumor, emergence of resistance, and multimodal AI https://t.co/9PhOrtkiBM @Cancer_Cell @ARPA_H
Cellular Reprogramming Paves Path to Anti‑Aging Organs
Anti-aging and organ rejuvenation strategies, a review https://t.co/ZycCqjZwKk @CellStemCell Figure summary of cellular reprogramming efforts https://t.co/YKgGKukuYb
Treg Breakthroughs: Nobel‑winning Science Moves Toward Clinics
The science of regulatory T cells (Tregs) got the @NobelPrize last year. Now a first-rate review of where they are headed in the clinical arena https://t.co/4xjNAeG3MV https://t.co/MZCDyBc4jq
FDA's Prasad Paradox: Conflicting Strictness on Bespoke Therapies
Predictions for cell therapy and gene therapy in 2026. Most interesting is the "Prasad Paradox", meaning a general state of contradiction at the FDA biologics division around laxness and strictness, including misapplication of the concept of "bespoke" therapies.
Cloning Error Deletes Lac Operator and T5 Promoter
Man, not my lucky day with cloning. A positive control plasmid had one of its lac operators and the -10 element of the T5 promoter removed during cloning. Gonna screen a few more. https://t.co/O09jf6Qf7F
Parabilis Secures $305M, CEO Signals IPO Plans
Mathai on quarterly conference calls? Parabilis Medicines raises $305 million as CEO warms to an IPO By @ADeAngelis_bio https://t.co/h6I9BXDuLS via @statnews
Ocular Therapeutix's Durable Eye Therapy Faces Upcoming Test
This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://t.co/XTI2wySnbB
